[Pubmed] Steroid-resistant minimal change nephrotic syndrome associated with thymoma treated effectively with rituximab
Posté : 09 févr. 2024 12:00
BMC Nephrol. 2024 Feb 9;25(1):53. doi: 10.1186/s12882-024-03485-2.
ABSTRACT
BACKGROUND: Minimal change nephrotic syndrome (MCNS) can be complicated by thymoma; however, no standard therapy for thymoma-associated MCNS has yet been established. We herein describe a case of steroid-resistant MCNS associated with thymoma, treated effectively with rituximab.
CASE PRESENTATION: A 71-year-old Japanese man was referred to our department with severe proteinuria (20 g/gCr). Renal biopsy showed minimal change disease and computed tomography revealed an anterior mediastinal mass. Based on these findings, he was diagnosed with thymoma-associated MCNS. He was treated with oral prednisolone (50 mg/day) and cyclosporine, and underwent thymectomy and plasma exchange. However, no improvement in proteinuria was observed. He therefore received intravenous rituximab 500 mg, resulting in a marked decrease in proteinuria from 5328 to 336 mg/day after 1 week.
CONCLUSIONS: This case suggests that rituximab might be an effective therapy in patients with steroid-resistant MCNS associated with thymoma.
PMID:38336671 | DOI:10.1186/s12882-024-03485-2
Source: https://pubmed.ncbi.nlm.nih.gov/3833667 ... 7&v=2.18.0